Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Biomarin Pharmaceutical's share price for the quarter that ended in Dec. 2023 was $96.42. Biomarin Pharmaceutical's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 189 Mil. Therefore, Biomarin Pharmaceutical's market cap for the quarter that ended in Dec. 2023 was $18,185 Mil.
Biomarin Pharmaceutical's quarterly market cap
increased
from Jun. 2023 ($16,309 Mil) to Sep. 2023 ($16,664 Mil) and
increased
from Sep. 2023 ($16,664 Mil) to Dec. 2023 ($18,185 Mil).
Biomarin Pharmaceutical's annual market cap
increased
from Dec. 2021 ($16,249 Mil) to Dec. 2022 ($19,275 Mil) but then
declined
from Dec. 2022 ($19,275 Mil) to Dec. 2023 ($18,185 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Biomarin Pharmaceutical's Enterprise Value for Today is $17,073 Mil.
Biomarin Pharmaceutical Market Cap Historical Data
The historical data trend for Biomarin Pharmaceutical's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Biomarin Pharmaceutical Annual Data
Trend
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
Market Cap
15,205.30
15,936.87
16,248.71
19,275.12
18,184.62
Biomarin Pharmaceutical Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
Market Cap
19,275.12
18,242.32
16,309.02
16,664.23
18,184.62
Competitive Comparison
For the Biotechnology subindustry, Biomarin Pharmaceutical's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biomarin Pharmaceutical Market Cap Distribution
For the Biotechnology industry and Healthcare sector, Biomarin Pharmaceutical's Market Cap distribution charts can be found below:
* The bar in red indicates where Biomarin Pharmaceutical's Market Cap falls into.
Biomarin Pharmaceutical Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Biomarin Pharmaceutical's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biomarin Pharmaceutical (NAS:BMRN) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Biomarin Pharmaceutical Market Cap Related Terms
Thank you for viewing the detailed overview of Biomarin Pharmaceutical's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Biomarin Pharmaceutical (Biomarin Pharmaceutical) Business Description
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the U.S. in 2023.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BMRN has been successfully added to your 